Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

HIV Infection

Free Subscription Articles published in Lancet Retrieve available abstracts of 95 articles: HTML format

Single Articles

October 2026
1. BEKKER LG, Neilan AM
   Closing the gap on mortality for adolescents living with HIV.
   Lancet. 2026;408:1402-1404.
   PubMed    
   
   
   September 2026
2. BRINK N, Butler R, Machingura F, Chersich M, et al
   Declare the climate crisis a Public Health Emergency of International Concern.
   Lancet. 2026 Sep 29:S0140-6736(26)01919-7. doi: 10.1016/S0140-6736(26)01919.
   PubMed    
   
   
   
3. BWAKURA-DANGAREMBIZI M, Chappell E, Kityo C, Anena DL, et al
   Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial.
   Lancet. 2026 Sep 17:S0140-6736(26)01537-0. doi: 10.1016/S0140-6736(26)01537.
   PubMed     Abstract available
   
   
   August 2026
4. COLSON AE, Kumar PN, Ruane PJ, Chetchotisakd P, et al
   Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.
   Lancet. 2026 Aug 12:S0140-6736(26)01442-X. doi: 10.1016/S0140-6736(26)01442.
   PubMed     Abstract available
   
   
   
5. DEL MAR ARCOS M, Arribas JR
   Once-weekly oral antiretroviral therapy for HIV.
   Lancet. 2026 Aug 12:S0140-6736(26)01557-6. doi: 10.1016/S0140-6736(26)01557.
   PubMed    
   
   
   
6. BISWAS S, Srivastava Y, Adepoju VA, Chintagumpala V, et al
   Power, dose, and fosfomycin in the SCOUT trial.
   Lancet. 2026;408:517.
   PubMed    
   
   
   
7. CUMMINGS MJ, Jacob ST, Bakamutumaho B
   Towards a globally relevant sepsis agenda: the role of HIV.
   Lancet. 2026;408:516.
   PubMed    
   
   
   
8. SINGER M, Machado FR, Kalil AC
   Towards a globally relevant sepsis agenda: the role of HIV - Authors' reply.
   Lancet. 2026;408:516-517.
   PubMed    
   
   
   July 2026
9. MORALEDA C, Tagarro A, Dominguez-Rodriguez S, Musiime V, et al
   Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial.
   Lancet. 2026 Jul 17:S0140-6736(26)00754-3. doi: 10.1016/S0140-6736(26)00754.
   PubMed     Abstract available
   
   
   
10. THE LANCET
    Ending HIV: a reality check.
    Lancet. 2026;408:93.
    PubMed    
    
    
    May 2026
11. LAXMINARAYAN R, Limmathurotsakul D, de Abreu AL, Alimi Y, et al
    Meeting the 2024 UN General Assembly declaration targets on antimicrobial resistance.
    Lancet. 2026 May 19:S0140-6736(26)00979-7. doi: 10.1016/S0140-6736(26)00979.
    PubMed    
    
    
    
12. MENDELSON M, Brink A
    Emerging beta-lactam and beta-lactamase inhibitor strategies for complicated urinary tract infections.
    Lancet. 2026;407:1893-1895.
    PubMed    
    
    
    April 2026
13. SHANKAR-HARI M, Ming D, Mendelson M, Rupali P, et al
    The Lancet Commission on Sepsis: transforming sepsis care and outcomes.
    Lancet. 2026 Apr 22:S0140-6736(26)00648-3. doi: 10.1016/S0140-6736(26)00648.
    PubMed    
    
    
    
14. CHARANI E, Makamu T, Silal S, Laxminarayan R, et al
    Rethinking country classifications towards a more equitable global health future.
    Lancet. 2026 Apr 2:S0140-6736(26)00457-5. doi: 10.1016/S0140-6736(26)00457.
    PubMed    
    
    
    March 2026
15. PAN D, Choi JS, Choi MJ, Phillips R, et al
    Respiratory virus research needs its own PPIE.
    Lancet. 2026;407:1144-1145.
    PubMed    
    
    
    
16. KASUJJA FX, Aikaeli F, Garrib A, van Widenfelt E, et al
    Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial.
    Lancet. 2026;407:1084-1094.
    PubMed     Abstract available
    
    
    
17. WONG N, Barnes D, Hartley J, Yunger P, et al
    Time to change internal medicine training for UK resident doctors.
    Lancet. 2026 Mar 6:S0140-6736(26)00290-4. doi: 10.1016/S0140-6736(26)00290.
    PubMed    
    
    
    February 2026
18. ORKIN C, Ruane PJ, Hedgcock M, Gaultier C, et al
    Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.
    Lancet. 2026 Feb 25:S0140-6736(26)00307-7. doi: 10.1016/S0140-6736(26)00307.
    PubMed     Abstract available
    
    
    
19. RATEVOSIAN J, Beyrer C
    Fundamental PEPFAR reform risks a period of structural vulnerability in the HIV response.
    Lancet. 2026 Feb 24:S0140-6736(26)00369-7. doi: 10.1016/S0140-6736(26)00369.
    PubMed    
    
    
    
20. COLSON AE, Mills AM, Ramgopal MN, Bettacchi C, et al
    Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, dou
    Lancet. 2026;407:611-621.
    PubMed     Abstract available
    
    
    
21. ORKIN C, Mngqibisa R, Velez JD, Kumar P, et al
    Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.
    Lancet. 2026;407:599-610.
    PubMed     Abstract available
    
    
    
22. ESTRADA V, Cabello-Clotet N
    Beyond integrase: the rise of doravirine and islatravir in HIV management.
    Lancet. 2026;407:551-553.
    PubMed    
    
    
    January 2026
23. GRIFFIN DWJ, McMahon JH, Hoy JF
    A call for equity in organ transplantation for people with HIV.
    Lancet. 2026;407:222-223.
    PubMed    
    
    
    December 2025
24. MAJAHA M, Chikwari CD, Kizito S, Moyo D, et al
    HIV and alcohol misuse among miners in Zimbabwe.
    Lancet. 2025;404:2538.
    PubMed    
    
    
    
25. VAKANIAKI EH, Barhishindi I, Mubiala A, Malembaka EB, et al
    Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study.
    Lancet. 2025 Dec 19:S0140-6736(25)02309-8. doi: 10.1016/S0140-6736(25)02309.
    PubMed     Abstract available
    
    
    
26. GREEN A
    Botswana's HIV services struggle.
    Lancet. 2025 Dec 17:S0140-6736(25)02585-1. doi: 10.1016/S0140-6736(25)02585.
    PubMed    
    
    
    
27. LUCKEY A, Balasegaram M, Barbee LA, Batteiger TA, et al
    Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.
    Lancet. 2025 Dec 11:S0140-6736(25)01953-1. doi: 10.1016/S0140-6736(25)01953.
    PubMed     Abstract available
    
    
    November 2025
28. THORNTON J
    Fiji faces major HIV outbreak.
    Lancet. 2025 Nov 30:S0140-6736(25)02430-4. doi: 10.1016/S0140-6736(25)02430.
    PubMed    
    
    
    
29. KARIM QA
    Lessons from Africa: health diplomacy in HIV prevention.
    Lancet. 2025 Nov 4:S0140-6736(25)01976-2. doi: 10.1016/S0140-6736(25)01976.
    PubMed    
    
    
    
30. MAYER KH, Beyrer C, Cohen MS, El-Sadr WM, et al
    Challenges and opportunities in developing integrated sexual and reproductive health programmes.
    Lancet. 2025;406:2168-2190.
    PubMed     Abstract available
    
    
    
31. MEYER-RATH G, Jamieson L, Mudimu E, Snyman K, et al
    Who pays and what pays off in sexual and reproductive health? A review of the cost and cost-effectiveness of interventions and implications for future funding and markets.
    Lancet. 2025;406:2152-2167.
    PubMed     Abstract available
    
    
    
32. PETERS RPH, Grinsztejn B, Celum C, Mayer KH, et al
    Innovations in the biomedical prevention, diagnosis, and service delivery of HIV and other sexually transmitted infections.
    Lancet. 2025;406:2133-2151.
    PubMed     Abstract available
    
    
    
33. GRULICH AE, Mercer CH, Sturrock B, Baral S, et al
    Partial progress in sexual and reproductive health and rights: the influence of sociocultural, behavioural, structural, and technological changes on epidemiological trends.
    Lancet. 2025;406:2100-2118.
    PubMed     Abstract available
    
    
    
34. NGEMA N
    A rights-based imperative for young women.
    Lancet. 2025;406:2038-2040.
    PubMed    
    
    
    October 2025
35. 
    Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01917-8. doi: 10.1016/S0140-6736(25)01917.
    PubMed     Abstract available
    
    
    
36. 
    Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01330-3. doi: 10.1016/S0140-6736(25)01330.
    PubMed     Abstract available
    
    
    
37. 
    Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Stud
    Lancet. 2025 Oct 12:S0140-6736(25)01637-X. doi: 10.1016/S0140-6736(25)01637.
    PubMed     Abstract available
    
    
    
38. BEKKER LG, Joseph Davey D, Saidi F
    Two for two: lenacapavir during pregnancy and lactation.
    Lancet. 2025;406:1560-1561.
    PubMed    
    
    
    September 2025
39. 
    The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Sep 24:S0140-6736(25)01635-6. doi: 10.1016/S0140-6736(25)01635.
    PubMed     Abstract available
    
    
    July 2025
40. BATHEJA D, Saint V, Dobreva Z, Goel S, et al
    Integrating gender and equity commitments in the revised global action plan on antimicrobial resistance.
    Lancet. 2025 Jul 16:S0140-6736(25)01377-7. doi: 10.1016/S0140-6736(25)01377.
    PubMed    
    
    
    
41. 
    Global HIV targets: a roadmap to 2030 and beyond.
    Lancet. 2025 Jul 16:S0140-6736(25)01449-7. doi: 10.1016/S0140-6736(25)01449.
    PubMed    
    
    
    
42. DUGDALE CM, Ufio O, Giardina J, Shebl F, et al
    Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: a systematic review and meta-analysis.
    Lancet. 2025 Jul 10:S0140-6736(25)00765-2. doi: 10.1016/S0140-6736(25)00765.
    PubMed     Abstract available
    
    
    
43. JOHN-STEWART G, Njuguna I
    Getting to zero: when can we guarantee vertical transmission of HIV will not occur?
    Lancet. 2025 Jul 10:S0140-6736(25)01282-6. doi: 10.1016/S0140-6736(25)01282.
    PubMed    
    
    
    
44. LAZARUS JV, Bansal MB, Kanwal F, Lofton H, et al
    Reflections on the Lancet Commission on Investing in Health's Global Health 2050 report.
    Lancet. 2025;406:30-31.
    PubMed    
    
    
    
45. HALLETT TB, Menzies NA, Resch S, Pretorius C, et al
    The case for optimal investment in combating HIV, tuberculosis, and malaria: a global modelling study.
    Lancet. 2025 Jul 3:S0140-6736(25)00831-1. doi: 10.1016/S0140-6736(25)00831.
    PubMed     Abstract available
    
    
    June 2025
46. CAVALCANTI DM, de Oliveira Ferreira de Sales L, da Silva AF, Basterra EL, et al
    Evaluating the impact of two decades of USAID interventions and projecting the effects of defunding on mortality up to 2030: a retrospective impact evaluation and forecasting analysis.
    Lancet. 2025 Jun 30:S0140-6736(25)01186-9. doi: 10.1016/S0140-6736(25)01186.
    PubMed     Abstract available
    
    
    
47. RAO S, Samalin-Scalzi E, Evesque L, Ben Abdelghani M, et al
    Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.
    Lancet. 2025;405:2144-2152.
    PubMed     Abstract available
    
    
    
48. BOZICEVIC I, Oreskovic S, van der Graaf R, McKee M, et al
    Open letter in support of WHO.
    Lancet. 2025 Jun 13:S0140-6736(25)01174-2. doi: 10.1016/S0140-6736(25)01174.
    PubMed    
    
    
    May 2025
49. SHIU C, Ho J, Aung MN, Chen WT, et al
    From disappointment to despair: USAID cuts to Myanmar's HIV services.
    Lancet. 2025 May 1:S0140-6736(25)00714-7. doi: 10.1016/S0140-6736(25)00714.
    PubMed    
    
    
    April 2025
50. ROSA WE, Connor S, Aggarwal G, Alsirafy S, et al
    Relieve the suffering: palliative care for the next decade.
    Lancet. 2025 Apr 18:S0140-6736(25)00678-6. doi: 10.1016/S0140-6736(25)00678.
    PubMed    
    
    
    
51. UNEMO M, Wi T
    Gepotidacin shows promise for the treatment of uncomplicated gonorrhoea.
    Lancet. 2025 Apr 11:S0140-6736(25)00680-4. doi: 10.1016/S0140-6736(25)00680.
    PubMed    
    
    
    
52. ROSS JDC, Wilson J, Workowski KA, Taylor SN, et al
    Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.
    Lancet. 2025 Apr 11:S0140-6736(25)00628-2. doi: 10.1016/S0140-6736(25)00628.
    PubMed     Abstract available
    
    
    
53. NDEMBI N, Karuna S, Cowden J, Cagigi A, et al
    Accelerating vaccine development in Africa: lessons from HIV research.
    Lancet. 2025 Apr 10:S0140-6736(25)00564-1. doi: 10.1016/S0140-6736(25)00564.
    PubMed    
    
    
    
54. SIDIBE M, Makgoba TC, Paul B, Brilliant B, et al
    Accelerating domestic investments to end AIDS in Africa.
    Lancet. 2025 Apr 8:S0140-6736(25)00685-3. doi: 10.1016/S0140-6736(25)00685.
    PubMed    
    
    
    
55. CLUVER L, Makangila G, Hillis S, Ntwali-N'Konzi JP, et al
    Protecting Africa's children from extreme risk: a runway of sustainability for PEPFAR programmes.
    Lancet. 2025 Apr 8:S0140-6736(25)00401-5. doi: 10.1016/S0140-6736(25)00401.
    PubMed     Abstract available
    
    
    
56. OKANO JT, Blower S
    Long-acting HIV preventive treatments for remote rural communities.
    Lancet. 2025;405:1143.
    PubMed    
    
    
    March 2025
57. AL ZAMEL AM, Saeed AA, Elmubarak M
    Sudan's war and the burden of HIV: a call for urgent intervention.
    Lancet. 2025 Mar 27:S0140-6736(25)00547-1. doi: 10.1016/S0140-6736(25)00547.
    PubMed    
    
    
    
58. PRASAD A
    Rachael Burke: integrating equitable HIV and TB research and care.
    Lancet. 2025 Mar 17:S0140-6736(25)00515-X. doi: 10.1016/S0140-6736(25)00515.
    PubMed    
    
    
    
59. PRASAD A
    Aliasgar Esmail: innovation in TB and HIV research and medicine.
    Lancet. 2025 Mar 17:S0140-6736(25)00514-8. doi: 10.1016/S0140-6736(25)00514.
    PubMed    
    
    
    
60. JOGIRAJU V, Pawar P, Yager J, Ling J, et al
    Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study.
    Lancet. 2025 Mar 10:S0140-6736(25)00405-2. doi: 10.1016/S0140-6736(25)00405.
    PubMed     Abstract available
    
    
    
61. RYOM L
    The potential for annual long-acting HIV pre-exposure prophylaxis.
    Lancet. 2025 Mar 10:S0140-6736(25)00452-0. doi: 10.1016/S0140-6736(25)00452.
    PubMed    
    
    
    
62. BARMANIA S
    Research focus: Institute of HIV Research and Innovation.
    Lancet. 2025;405:771.
    PubMed    
    
    
    
63. TRAJMAN A, Campbell JR, Kunor T, Ruslami R, et al
    Tuberculosis.
    Lancet. 2025;405:850-866.
    PubMed     Abstract available
    
    
    February 2025
64. DEVI S
    A new era for HIV in the Philippines?
    Lancet. 2025;405:611-612.
    PubMed    
    
    
    
65. HOLT E
    Ukraine HIV services severely curtailed by US aid freeze.
    Lancet. 2025;405:455.
    PubMed    
    
    
    
66. RATEVOSIAN J, Millett G, Honermann B, Bennett S, et al
    PEPFAR under review: what's at stake for PEPFAR's future.
    Lancet. 2025 Feb 7:S0140-6736(25)00258-2. doi: 10.1016/S0140-6736(25)00258.
    PubMed    
    
    
    January 2025
67. BROSIUS I, Vakaniaki EH, Mukari G, Munganga P, et al
    Epidemiological and clinical features of mpox during the clade Ib outbreak in South Kivu, Democratic Republic of the Congo: a prospective cohort study.
    Lancet. 2025 Jan 29:S0140-6736(25)00047-9. doi: 10.1016/S0140-6736(25)00047.
    PubMed     Abstract available
    
    
    
68. KAMAL-YANNI M, Gangte L, Kittitrakul C, Meyer S, et al
    Is MSF changing course on access to medicines?
    Lancet. 2025;405:124-125.
    PubMed    
    
    
    November 2024
69. THE LANCET
    Triumphs and threats: HIV in 2024.
    Lancet. 2024;404:2131.
    PubMed    
    
    
    
70. BENDER IGNACIO RA, Shapiro AE, Montano MA, Titanji BK, et al
    An urgent call to address the intersection of mpox and HIV in Africa.
    Lancet. 2024 Nov 28:S0140-6736(24)02542-X. doi: 10.1016/S0140-6736(24)02542.
    PubMed    
    
    
    
71. NORHEIM OF, Chang AY, Bolongaita S, Barraza-Llorens M, et al
    Halving premature death and improving quality of life at all ages: cross-country analyses of past trends and future directions.
    Lancet. 2024 Nov 20:S0140-6736(24)02417-6. doi: 10.1016/S0140-6736(24)02417.
    PubMed     Abstract available
    
    
    
72. COUSINS S
    New HIV drugs: access debates.
    Lancet. 2024;404:1797-1798.
    PubMed    
    
    
    September 2024
73. SALEH E, Dousa KM, Babiker A, Rahma NEAA, et al
    Health and humanitarian toll of Sudan's forgotten war.
    Lancet. 2024 Sep 24:S0140-6736(24)01939-1. doi: 10.1016/S0140-6736(24)01939.
    PubMed    
    
    
    August 2024
74. KIZITO S, Nabayinda J, Nabunya P, Ssewamala FM, et al
    HIV and tuberculosis in Uganda: are we neglecting poverty?
    Lancet. 2024;404:844-845.
    PubMed    
    
    
    
75. BASSEY AE
    The health of migrants at the intersection of mpox and HIV.
    Lancet. 2024 Aug 23:S0140-6736(24)01753-7. doi: 10.1016/S0140-6736(24)01753.
    PubMed    
    
    
    
76. MODY A, Sohn AH, Iwuji C, Tan RKJ, et al
    The battle against paediatric HIV is far from over - Authors' reply.
    Lancet. 2024;404:522-523.
    PubMed    
    
    
    
77. VAN DE PERRE P, Tylleskar T
    The battle against paediatric HIV is far from over.
    Lancet. 2024;404:522.
    PubMed    
    
    
    
78. NABAYINDA J, Kizito S, Nagawa A, Ssewamala FM, et al
    Reducing HIV in young women in Uganda: the need for autonomy.
    Lancet. 2024;404:519-520.
    PubMed    
    
    
    
79. SALEEM SM, Haq Z
    Bridging gaps in vertical transmission of HIV, syphilis, and hepatitis B in India.
    Lancet. 2024;404:428-429.
    PubMed    
    
    
    July 2024
80. KIRBY T
    Beatriz Grinsztejn: leading Brazil's response to HIV.
    Lancet. 2024;404:233.
    PubMed    
    
    
    May 2024
81. JAFFAR S
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa - Authors' reply.
    Lancet. 2024;403:2292.
    PubMed    
    
    
    
82. CAI S, Xu Z, Zhao Y, Zuhlke L, et al
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291.
    PubMed    
    
    
    
83. HAVLIR D, Kamya MR, Petersen M
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291-2292.
    PubMed    
    
    
    
84. MAERTENS GN, Purcell DFJ, Rosadas C, Bradshaw D, et al
    Why not eliminate HTLV-1 while eliminating HIV-1?
    Lancet. 2024;403:2288-2289.
    PubMed    
    
    
    
85. 
    The HIV response beyond 2030: preparing for decades of sustained HIV epidemic control in eastern and southern Africa.
    Lancet. 2024 May 20:S0140-6736(24)00980-2. doi: 10.1016/S0140-6736(24)00980.
    PubMed    
    
    
    
86. LEWNARD JA, Charani E, Gleason A, Hsu LY, et al
    Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis.
    Lancet. 2024 May 20:S0140-6736(24)00862-6. doi: 10.1016/S0140-6736(24)00862.
    PubMed     Abstract available
    
    
    
87. MENDELSON M, Lewnard JA, Sharland M, Cook A, et al
    Ensuring progress on sustainable access to effective antibiotics at the 2024 UN General Assembly: a target-based approach.
    Lancet. 2024 May 20:S0140-6736(24)01019-5. doi: 10.1016/S0140-6736(24)01019.
    PubMed     Abstract available
    
    
    April 2024
88. TUTLAM NT, Kizito S, Liyew TW, Ssewamala FM, et al
    HIV among refugee youth in Uganda: unmasking the crisis.
    Lancet. 2024;403:1536-1537.
    PubMed    
    
    
    
89. 
    Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a sys
    Lancet. 2024 Apr 15:S0140-6736(24)00757-8. doi: 10.1016/S0140-6736(24)00757.
    PubMed     Abstract available
    
    
    
90. 
    Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024 Apr 3:S0140-6736(24)00367-2. doi: 10.1016/S0140-6736(24)00367.
    PubMed     Abstract available
    
    
    March 2024
91. BEYRER C, Kamarulzaman A, Isbell M, Amon J, et al
    Under threat: the International AIDS Society-Lancet Commission on Health and Human Rights.
    Lancet. 2024 Mar 20:S0140-6736(24)00302-7. doi: 10.1016/S0140-6736(24)00302.
    PubMed    
    
    
    
92. WATTS G
    Andrew Kerkhoff: award-winning TB and HIV physician-scientist.
    Lancet. 2024 Mar 15:S0140-6736(24)00539-7. doi: 10.1016/S0140-6736(24)00539.
    PubMed    
    
    
    
93. KANKASA C, Mennecier A, Sakana BLD, Moles JP, et al
    Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial.
    Lancet. 2024 Mar 11:S0140-6736(23)02464-9. doi: 10.1016/S0140-6736(23)02464.
    PubMed     Abstract available
    
    
    
94. MUTALE W, Herce ME
    Closing the gap in paediatric HIV infections: how available tools and technology can accelerate progress towards ending AIDS by 2030.
    Lancet. 2024 Mar 11:S0140-6736(24)00366-0. doi: 10.1016/S0140-6736(24)00366.
    PubMed    
    
    
    
95. 
    Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden
    Lancet. 2024 Mar 8:S0140-6736(24)00476-8. doi: 10.1016/S0140-6736(24)00476.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum